Media coverage about Cerus Corporation (NASDAQ:CERS) has trended positive this week, Accern Sentiment reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cerus Corporation earned a media sentiment score of 0.32 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.5884309695537 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

Several research firms recently commented on CERS. BidaskClub upgraded Cerus Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Zacks Investment Research upgraded Cerus Corporation from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Wednesday, November 8th. Cowen and Company set a $6.00 price target on Cerus Corporation and gave the stock a “buy” rating in a research report on Thursday, October 5th. Finally, ValuEngine lowered Cerus Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Cerus Corporation has a consensus rating of “Hold” and a consensus price target of $6.40.

Shares of Cerus Corporation (NASDAQ:CERS) remained flat at $$3.60 during trading hours on Monday. 509,600 shares of the company traded hands, compared to its average volume of 1,009,624. Cerus Corporation has a twelve month low of $1.93 and a twelve month high of $5.91. The company has a debt-to-equity ratio of 0.80, a quick ratio of 3.11 and a current ratio of 3.71.

Cerus Corporation (NASDAQ:CERS) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. Cerus Corporation had a negative return on equity of 142.18% and a negative net margin of 159.35%. The business had revenue of $10.80 million during the quarter, compared to analyst estimates of $11.95 million. During the same quarter in the previous year, the business earned ($0.14) earnings per share. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. equities research analysts forecast that Cerus Corporation will post -0.59 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Positive News Coverage Somewhat Unlikely to Impact Cerus Corporation (CERS) Share Price” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at

About Cerus Corporation

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Insider Buying and Selling by Quarter for Cerus Corporation (NASDAQ:CERS)

Receive News & Stock Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related stocks with our FREE daily email newsletter.